• Vol. 44 No. 10, 388–396
  • 15 October 2015

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma

ABSTRACT

Introduction: The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore.

Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.

Results: Five international guidelines were evaluated—those developed by the National Cancer Comprehensive Network (2014), the European Society of Medical Oncology (2012), Cancer Care Ontario (2013), the Japan Pancreas Society (2013) and the British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, and the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (2005). Recommendations on the management of resected, borderline resectable, locally advanced and metastatic pancreatic adenocarcinoma were developed.

Conclusion: These adapted guidelines form the SCAN Guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore


Worldwide, pancreatic cancer is the thirteenth most common adult malignancy and the seventh most common cause of cancer death. In Singapore, it is the eleventh and twelfth most common cancer among Singaporean men and women respectively. Although pancreatic cancer did not feature among the 10 most common cancers in Singapore, it represented the fifth and seventh most common cause of cancer death in Singaporean males and females, respectively. This is because of the late presentation exhibited by most patients.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.